期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Concurrent chemoradiotherapy combined with enteral nutrition support:a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant istulae 被引量:19
1
作者 Li Ma Guang-Yu Luo +12 位作者 Yu-Feng Ren Bo Qiu Hong Yang Chun-Xia Xie Song-Ran Liu Shi-Liang Liu zhao-lin chen Qun Li Jian-Hua Fu Meng-Zhong Liu Yong-Hong Hu Wen-Feng Ye Hui Liu 《Chinese Journal of Cancer》 SCIE CAS CSCD 2017年第1期26-33,共8页
Background: Concurrent chemoradiotherapy(CCRT) significantly increases the survival rate of esophageal squa?mous cell carcinoma(ESCC) patients with malignant fistulae. Recent clinical evidence has shown the benefits o... Background: Concurrent chemoradiotherapy(CCRT) significantly increases the survival rate of esophageal squa?mous cell carcinoma(ESCC) patients with malignant fistulae. Recent clinical evidence has shown the benefits of enteral nutrition for malnourished cancer patients. In this study, we aimed to validate that, with the support of enteral nutrition, ESCC patients who develop malignant fistulae might be able to complete CCRT and achieve long?term survival.Methods: We reviewed the medical records of 652 patients with ESCC who received definitive CCRT at Sun Yat?sen University Cancer Center between January 2010 and December 2012. Treatment outcome and toxicity were ret?rospectively evaluated in 40 ESCC patients with malignant fistulae. All the 40 patients were treated with CCRT and evaluated by clinical nutritionists using nutrition risk screening(NRS) before, during, and after treatment. Twenty?two patients received a nasogastric tube, and 18 underwent percutaneous endoscopic gastrostomy feeding. The median energy intake was 2166 kcal/day. Treatment response was evaluated at 3 months after the completion of CCRT.Results: With a median follow?up of 18 months(range, 3–39 months), patients' 1?year overall survival(OS) rate was 62.5%, and the estimated OS time was 25.5 months. Univariate analysis showed that the NRS score(P n NRS score(P se to treatment(P < 0.001) were sig= 0.003), increase i= 0.024), fistula closure(P = 0.011), and responnifi?cantly associated with OS. Multivariate analysis showed that tumor response(P = 0.044) and increase in NRS score(P = 0.044) were independent predictors of OS. Grade 3 vomiting was observed in 8 patients(20.0%), grade 3 neutro?penia was observed in 11 patients(27.5%), and grade 3 cough was observed in 13 patients(32.5%); 2 patients(5.0%) died of massive bleeding during treatment.Conclusions: CCRT combined with enteral nutrition support is effective for ESCC patients with malignant fistulae. Patients have an increased potential to be cured, especially those who experience complete response and have an increase in NRS score. Careful observation and nutrition support are required for patients with advanced T?category ESCC who undergo CCRT. 展开更多
关键词 Esophageal squamous cell carcinoma Malignant istula RADIOTHERAPY Concurrent chemotherapy Enteral nutrition support
下载PDF
Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy 被引量:8
2
作者 Li Ma Bo Qiu +7 位作者 Jun Zhang Qi-Wen Li Bin Wang Xu-Hui Zhang Meng-Yun Qiang zhao-lin chen Su-Ping Guo Hui Liu 《Chinese Journal of Cancer》 SCIE CAS CSCD 2017年第11期657-664,共8页
Background: Locoregional recurrence remains the challenge for long-term survival of non-small cell lung cancer(NSCLC) patients after radical surgery, and curative-intent radiotherapy could be a treatment choice. This ... Background: Locoregional recurrence remains the challenge for long-term survival of non-small cell lung cancer(NSCLC) patients after radical surgery, and curative-intent radiotherapy could be a treatment choice. This study aimed to assess the survival and prognostic factors of patients with postoperative locoregionally recurrent NSCLC treated with radical radiotherapy.Methods: We reviewed medical records of 74 NSCLC patients with postoperative locoregional recurrence who received radical radiotherapy between April 2012 and February 2016 at Sun Yat-sen University Cancer Center(Guangzhou, China). The efficacy and safety of radical radiotherapy were analyzed. The probability of survival was estimated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used to identify prognostic factors.Results: Grade 3/4 adverse events included neutropenia(8 cases, 10.8%), esophagitis(7 cases, 9.5%), pneumonitis(1 case, 1.4%), and vomiting(1 case, 1.4%).The 2-year overall survival, progression-free survival, local recurrencefree survival(LRFS), and distant metastasis-free survival(DMFS) rates of all patients were 84.2,42.5,70.0, and 50.9%,respectively. Univariate and multivariate analyses showed that a higher biological effective dose(BED) of radiation was associated with longer LRFS [hazard ratios(HR)=0.317,95% confidence interval(CI) = 0.112-0.899, P = 0.016] and that wild-type epidermal growth factor receptor(EGFR) was associated with longer DMFS compared with EGFR mutation(HR = 0.383,95% CI=0.171-0.855, P = 0.019).Conclusions: Radical radiotherapy is effective and well-tolerated in NSCLC patients with postoperative locoregional recurrence. High BED is a predictor for long LRFS, and the presence of wild-type EGFR is a predictor for long DMFS. 展开更多
关键词 NON-SMALL cell lung cancer LOCOREGIONAL RECURRENCE RADICAL radiotherapy Biological effective dose EPIDERMAL growth factor receptor
下载PDF
非小细胞肺癌术后局部复发患者接受根治性放疗的生存及预后因素 被引量:3
3
作者 Li Ma Bo Qiu +7 位作者 Jun Zhang Qi-Wen Li Bin Wang Xu-Hui Zhang Meng-Yun Qiang zhao-lin chen Su-Ping Guo Hui Liu 《癌症》 SCIE CAS CSCD 2018年第4期161-169,共9页
背景与目的局部复发是影响根治性手术后非小细胞肺癌(non?small cell lung cancer,NSCLC)患者长期生存的重要因素之一,而根治性放疗可作为解决这一问题的可选治疗方案。本研究旨在评价接受根治性放疗的NSCLC术后局部复发患者的生存和预... 背景与目的局部复发是影响根治性手术后非小细胞肺癌(non?small cell lung cancer,NSCLC)患者长期生存的重要因素之一,而根治性放疗可作为解决这一问题的可选治疗方案。本研究旨在评价接受根治性放疗的NSCLC术后局部复发患者的生存和预后因素。方法回顾2012年4月至2016年2月期间,在中山大学肿瘤防治中心接受根治性放疗的74例NSCLC术后局部复发患者的病历资料,分析根治性放疗的疗效和安全性。采用Kaplan-Meier法估算患者生存率,并用log-rank检验进行比较,采用Cox回归模型进行单、多因素分析。结果 3/4级不良事件包括中性粒细胞减少(8例,10.8%)、放射性食管炎(7例,9.5%)、放射性肺炎(1例,1.4%)和呕吐(1例,1.4%)。所有患者的2年总生存率、无进展生存率、局部无复发生存(local recurrence?free survival,LRFS)率和无远处转移生存(distant metastasis?free survival,DMFS)率分别为84.2%、42.5%、70.0%和50.9%。单因素和多因素分析显示,较高的生物等效剂量(biological effective dose,BED)与较长的LRFS相关(风险比[hazard ratios,HR]=0.317,95%置信区间[confidence interval,CI]:0.112–0.899,P=0.016),与表皮生长因子受体(epidermal growth factor receptor,EGFR)突变型患者相比,EGFR野生型患者的DMFS较长(HR=0.383,95%CI:0.171–0.855,P=0.019)。结论对于NSCLC术后局部复发患者应用根治性放疗治疗是安全有效的。BED与LRFS呈正相关,EGFR野生型患者DMFS较长。 展开更多
关键词 非小细胞肺癌 局部复发 根治性放疗 生物等效剂量 表皮生长因子受体
下载PDF
同步放化疗联合肠内营养支持:食管鳞状细胞癌合并恶性瘘患者的根治策略 被引量:1
4
作者 Li Ma Guang-Yu Luo +12 位作者 Yu-Feng Ren Bo Qiu Hong Yang Chun-Xia Xie Song-Ran Liu Shi-Liang Liu zhao-lin chen Qun Li Jian-Hua Fu Meng-Zhong Liu Yong-Hong Hu Wen-Feng Ye Hui Liu 《癌症》 SCIE CAS CSCD 2018年第9期413-420,共8页
背景与目的同步放化疗(concurrent chemoradiotherapy,CCRT)可显著提高食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)合并恶性瘘患者的生存率。最近的临床证据已经表明营养不良患者可从肠内营养中获益。本研究旨在验证在肠... 背景与目的同步放化疗(concurrent chemoradiotherapy,CCRT)可显著提高食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)合并恶性瘘患者的生存率。最近的临床证据已经表明营养不良患者可从肠内营养中获益。本研究旨在验证在肠内营养支持下,发生恶性瘘的ESCC患者可能完成CCRT,并获得长期生存。方法我们回顾了2010年1月至2012年12月在中山大学肿瘤防治中心接受根治性CCRT的652例ESCC患者的病历。回顾性评价了40例食管癌合并恶性瘘患者的治疗结局及毒副反应。40例患者均接受了CCRT治疗,治疗前、中、后由临床营养师进行营养风险筛查(nutrition risk screening,NRS)评价。22例患者接受鼻胃管,18例接受经皮内镜胃造瘘术营养支持。中位能量摄入量为2166 kcal/d。在CCRT完成后的第3个月进行治疗反应评估。结果中位随访时间为18个月(范围:3–39个月),患者1年总生存(overall survival,OS)率为62.5%,估计OS的时间为25.5个月。单因素分析显示,NRS评分(P=0.003)、NRS评分增加(P=0.024)、瘘闭合(P=0.011)、治疗反应(P <0.001)与OS显著相关。多因素分析显示肿瘤反应(P=0.044)和NRS评分增加(P=0.044)是OS的独立预后因素。观察到3级呕吐8例(20.0%),3级中性粒细胞减少症11例(27.5%),3级咳嗽13例(32.5%),治疗期间死于大出血2例(5.0%)。结论 CCRT联合肠内营养支持治疗ESCC合并恶性瘘患者是有效的;患者治愈机会增加,尤其是那些完全缓解并表现NRS评分增加的患者。需要对接受CCRT的T分期较晚ESCC患者仔细观察和营养支持。 展开更多
关键词 食管鳞状细胞癌 恶性瘘 放疗 同步化疗 肠内营养支持
下载PDF
MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent of liver cancer
5
作者 zhao-lin chen Tao-Tao Ma +3 位作者 cheng Huang Tao Xu Ting-Ting Hu Jun Li 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2013年第6期661-661,共1页
The Editor welcomes submissions for possible publication in the Letters to the Editor section.Letters commenting on an article published in the Journal or other interesting pieces will be considered if they are receiv... The Editor welcomes submissions for possible publication in the Letters to the Editor section.Letters commenting on an article published in the Journal or other interesting pieces will be considered if they are received within 6 weeks of the time the article was published.Authors of the article being commented on will be given an opportunity to offer a timely response to the letter.Authors of letters will be notified that the letter has been received.Unpublished letters cannot be returned. 展开更多
关键词 HCC MicroRNA-216a a potential therapeutic target for drug resistance and recurrent of liver cancer
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部